Article

Prognostic and potential therapeutic roles of PRKDC expression in lung cancer

2023-11-14

Abstract excerpt

PRKDC is a key factor involved in the ligation step of the non-homologous end joining pathway. Its dysfunction has proven to be a biomarker for radiosensitivity of cancer cells. Our previous study has shown that PRKDC mutations is associated with tumor immune response. However, the prognostic value of PRKDC at transcriptome levels and the underlying mechanisms have not been clarified yet. In this study, we analyze...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 72dc76ed-119a-5ad0-83bd-1869aabcf629
DOI: 10.21203/rs.3.rs-3582455/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Prognostic and potential therapeutic roles of PRKDC expression in lung cancerDOI 10.21203/rs.3.rs-3582455/v1Read

The Prognostic and Therapeutic Potential of DNA Damage Repair Pathway Alterations and Homologous Recombination Deficiency in Lung CancerSemantic proximity Read

Potential Value of PRKDC as a Therapeutic Target and Prognostic Biomarker in Pan-CancerSemantic proximity Read

Expression and clinical significance of PRKDC in lung cancer based on bioinformatics analysisSemantic proximity Read

Clinical and molecular significance of homologous recombination deficiency positive non-small cell lung cancer in Chinese population: An integrated genomic and transcriptional analysisSemantic proximity Read

Mutational landscape of homologous recombination-related genes in small-cell lung cancer.Semantic proximity Read

HRD1 in human malignant neoplasms: Molecular mechanisms and novel therapeutic strategy for cancerSemantic proximity Read

DNA damage response and repair gene mutations are associated with tumor mutational burden and outcomes to platinum-based chemotherapy/immunotherapy in advanced NSCLC patients.Semantic proximity Read

Targeting the DNA Damage Response Machinery for Lung Cancer TreatmentSemantic proximity Read

PRKDC : new biomarker and drug target for checkpoint blockade immunotherapySemantic proximity Read

Homologous recombination deficiency (HRD) can predict the therapeutic outcomes of immuno-neoadjuvant therapy in NSCLC patientsSemantic proximity Read

Bioinformatic analysis revealing mitotic spindle assembly regulated NDC80 and MAD2L1 as prognostic biomarkers in non-small cell lung cancer developmentSemantic proximity Read

NCAPD2 Is a Favorable Predictor of Prognostic and Immunotherapeutic Biomarker for Multiple Cancer Types Including Lung CancerSemantic proximity Read